Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies

• Natali Pflug,
• Geothy Chakupurakal,
• Anna-Maria Fink,
• Sandra Robrecht,
• Marco Herling,
• Paula Cramer,
• Udo Holtick,
• Sebastian Theurich,
• Johannes Schetelig,
• Kirsten Fischer,
• Matthias Ritgen,
• Christof Scheid,
• Barbara Eichhorst,
• Peter Dreger,
• Michael Hallek,
• Michael von Bergwelt-Baildon,
• on behalf of the German CLL Study Group

Affiliations

Natali Pflug

1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Geothy Chakupurakal

2 Praxis für Hämatologie und Onkologie, Koblenz, Germany

Anna-Maria Fink

1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Sandra Robrecht

1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Marco Herling

1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Paula Cramer

1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Udo Holtick

1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Sebastian Theurich

1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Johannes Schetelig

6 Medizinische Klinik und Poliklinik I, University Hospital Dresden, Germany

Kirsten Fischer

1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Matthias Ritgen

8 University Clinic of Schleswig-Holstein, Kiel, Germany

Christof Scheid

1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Barbara Eichhorst

1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Peter Dreger

9 Department of Medicine V, University Hospital Heidelberg, Germany

Michael Hallek

1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

Michael von Bergwelt-Baildon

1 Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), University of Cologne, Germany

on behalf of the German CLL Study Group